Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3529]

ESMO GI: PV-10 shows potential in hepatocellular carcinoma and metastatic liver disease

ESMO GI: PV-10 shows potential in hepatocellular carcinoma and metastatic liver disease

Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

How cancer tricks the lymphatic system into spreading tumours

How cancer tricks the lymphatic system into spreading tumours

IARC evaluates carcinogenic status of DDT, lindane and 2,4-D

IARC evaluates carcinogenic status of DDT, lindane and 2,4-D

Josep Tabernero to head ESMO

Josep Tabernero to head ESMO

European Commission approves nivolumab for first-line and previously-treated advanced melanoma patients

European Commission approves nivolumab for first-line and previously-treated advanced melanoma patients

EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease...

Rolling submission of Biologic License Application initiated for daratumumab with US FDA for multiple myeloma

Rolling submission of Biologic License Application initiated for daratumumab with US FDA for multiple myeloma

Mouse models of human colorectal cancer generated through chemokine targeting

Mouse models of human colorectal cancer generated through chemokine targeting

ASCO 2015: Pembrolizumab may be promising treatment for urothelial cancer

ASCO 2015: Pembrolizumab may be promising treatment for urothelial cancer

More from ecancer